Neurogene Unveils Embolden Trial Design for NGN-401 in Rett Syndrome
July 1, 2025
Written agreement from FDA to evaluate NGN-401 in females with Rett syndrome ages 3 years and older based on natural history study analysis Neurogene Inc.,